Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sialic acid-binding immunoglobulin-like lectin 8 (SIGLEC8)
- Target
- SIGLEC8
- Molecular classification
- Receptor, Lectins, Type I transmembrane protein, Immunoglobulin-like lectin, Siglec, CD33-related Siglec
01
Overview
SIGLEC8 is an immune-inhibitory receptor selectively expressed on eosinophils, mast cells, and basophils. As a member of the CD33-related Siglec family, it binds to α2,3-linked sialic acids, particularly those containing sulfated galactose residues such as 6'-sulfo sialyl Lewis^x. Engagement of SIGLEC8 induces eosinophil apoptosis and inhibits mast cell degranulation, making it a promising therapeutic target for eosinophilic and allergic diseases.
02
Mechanism of action
Agonistic monoclonal antibodies or glycan ligands bind to SIGLEC8, inducing eosinophil apoptosis via Src/Syk/PI3K/PLC/PKC/Rac1-MEK1–ERK/CD11b-CD18 integrin pathways or inhibiting mast cell degranulation.
03
Biological functions
Immune responseApoptosisInhibition of mast cell degranulationRegulation of eosinophil functionCell signaling
04
Disease associations
Eosinophilic disordersAsthmaAllergic diseasesEosinophilic gastritisChronic inducible urticariaInflammation
05
Safety considerations
Potential for off-target effects on other immune cellsRisk of excessive eosinophil depletionPossible immune suppression
06
Interacting drugs
Monoclonal antibodies (agonistic)
1 more in the full profile.
07
Biomarkers
Soluble SIGLEC8 levels in serumEosinophil countMast cell activation markers
Beyond the preview
Go deeper on Sialic acid-binding immunoglobulin-like lectin 8 (SIGLEC8).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sialic acid-binding immunoglobulin-like lectin 8 (SIGLEC8).